Importantly, recent global studies have reported a higher risk of genital Candida infections among individuals with type 2 diabetes, particularly those receiving sodium–glucose cotransporter-2 (SGLT2) inhibitor therapy, owing to glucosuria, altered mucosal immunity, and enhanced fungal proliferation under hyperglycemic conditions [6,7,8,9,10,11,12]. The gene discussed is SLC5A2; the disease is candidiasis.